Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT

作者：Jakob Robert Passweg, Helen Baldomero, Tobias Alexander, Emanuele Angelucci, Diana Averbuch, Ali A. Bazarbachi, Fabio Ciceri, Raffaella Greco, Mette D. Hazenberg, Krzysztof Kałwak, Donal P. McLornan, Antonio Maria Risitano, Annalisa Ruggeri, John Andrew Snowden, Anna Sureda · 发表于：Bone Marrow Transplantation · 年份：2024 · DOI：10.1038/s41409-024-02459-0 · 被引用次数：16 · 研究领域：CAR-T cell therapy research、Biomedical Ethics and Regulation、Pluripotent Stem Cells Research

We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received advanced cellular therapies, 3205 were CAR-T. We found considerable differences in utilization of autologous, allogeneic HCT and more so for CAR-T. Differences in procedure type and for allogeneic HCT in donor use and disease indication are highlighted. For instance, countries with the highest use of unrelated donors per 10 million inhabitants were Germany (297) and the Netherlands (230), for identical sibling HCT it was Israel (148) and Lebanon (113), for haploidentical it was Israel (94) and Italy (94) and for cord blood it was the Netherlands (24) and the United Kingdom (15). We looked at HCT use for specific indications in allogeneic HCT (AML CR1, MDS, MPN and BMF). We correlated treatment rates with GNI and with demographic age structure and show correlations in HCT and CAR-T use and center density, highest in Italy for allogeneic and autologous HCT and in Switzerland for CAR-T. Resource restricted countries tend to concentrate HCT use in a limited number of centers. These data are useful for comparisons across countries.